FDA warns Detroit investigator over pediatric drug trial protocol deviations and lapsed IRB approval.
What happened
FDA inspected Dr. Taub's clinical site from September 23, 2022, to October 12, 2022, as part of its Bioresearch Monitoring Program. FDA found that a 6-year-old subject received three extra doses and three extra five-day cycles of study drugs, and that study drug was dispensed and blood and bone marrow samples were collected while institutional review board (IRB) approval had lapsed from January 14, 2022, to January 24, 2022. FDA reviewed the site's October 27, 2022, and January 10, 2023, responses to the Form FDA 483 inspection observations and found the corrective action plans lacked sufficient detail.
What FDA found
The investigator did not make sure the study followed the investigational plan; a 6-year-old subject received three extra doses and three extra five-day cycles of study drugs, increasing risk of serious nerve and blood toxicities.
21 CFR 312.60The investigator did not make sure a compliant institutional review board (IRB) reviewed and approved the study continuously; IRB approval lapsed from January 14 to January 24, 2022, while study drug was dispensed and blood and bone marrow samples were collected.
21 CFR 312.66
What FDA wants
Within 15 business days of receiving the letter, Dr. Taub must write to FDA describing actions taken to prevent similar violations. FDA also asks for follow-up documentation on site policies and procedures for protocol compliance, randomization assignments, and timely IRB continuing review.
Who should pay attention
- clinical investigators running pediatric oncology trials
- IRBs and research sites overseeing human-subject studies
- sponsors and contract research organizations monitoring protocol and IRB compliance
This is a summary. Read the original letter on fda.gov.